Crohn’s disease (CD) is a chronic, progressive inflammatory bowel disease that frequently becomes refractory to conventional and biologic therapies, resulting in significant morbidity, repeated surgeries, and impaired quality of life. Autologous hematopoietic stem cell transplantation (AHSCT) offers a potential immune reset through immunoablation followed by hematopoietic reconstitution. This prospective observational study assessed the safety, feasibility, clinical remission, endoscopic response, and long-term outcomes of AHSCT in patients with severe, treatment-refractory CD. AHSCT is feasible and demonstrates promising rates of clinical and endoscopic remission in carefully selected patients with refractory CD, with an acceptable safety profile in an experienced center. These results align with recent international consortium data and support further evaluation of optimized regimens in larger multicenter trials.

Autologous hematopoietic stem cell transplantation, Crohn’s disease, refractory inflammatory bowel disease, immunoablation, clinical remission, endoscopic healing, quality of life

Lindsay JO, et al. Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(4):333-345.

Hawkey CJ, et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA. 2015;314(23):2524-2534.

Guisado D, et al. Outcomes from the international stem cell transplant consortium for refractory Crohn’s disease. J Crohns Colitis. 2025;19(Suppl 1):i9.

Brierley CK, et al. Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation. J Crohns Colitis. 2018;12(5):S1-S2.

Gupta A, et al. Hematopoietic stem cell transplantation in Crohn’s disease. Curr Opin Gastroenterol. 2025;41(4):XXX-XXX. (Additional references from EBMT registry, systematic reviews, and long-term follow-up studies are available upon request.)

Gazkhanovna, M. A., Makhmatovich, A. K., & Utkirovich, D. U. (2022). Clinical efficacy of extracorporeal and intravascular hemocorrection methods in psoriasis. Academicia: An International Multidisciplinary Research Journal, 12(2), 313-318.

Madasheva, A. G., & Abdiev, K. M. (2023). Blood transfusion therapy in patients with vitamin B12 deficiency anemia after resection of 2/3 of the stomach. Science and Education, 4(5), 407-412.

Мадашева, А. Г., & Жураева, М. З. (2019). Биохимические показатели и комплексное лечение больных псориазом с лечебным плазмаферезом. Достижения науки и образования, (10 (51)), 78-82.

Мадашева, А., Бергер, И., Махмудова, А., Абдиев, К., & Амерова, Д. (2025). Лабораторная диагностика. восточная европа. лабораторная диагностика, 14(1), 87-96.

Мадашева, А. Г. (2022). Клинико-неврологические изменения у больных гемофилией с мышечными патологиями. Science and Education, 3(12), 175-181.

Мадашева, А. Г. (2022). Коррекция диффузной алопеции при железодефицитной анемии. Science and Education, 3(12), 231-236.

Мадашева, А. Г., Дадажанов, У. Д., Абдиев, К. М., Маматкулова, Ф. Х., & Махмудова, А. Д. (2019). Динамика электронейромиографических показателей и эффективность электрической стимуляции мышц у больных гемофилией с мышечными атрофиями. Достижения науки и образования, (10 (51)), 26-30.